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Abstract
New understanding of the underlying pathology of the thrombotic microangiopathies has resulted in
guidelines for the investigation and management of atypical haemolytic uraemic syndrome in children
and adults and the prospect of new therapies, which are in clinical trial. Patients should be
investigated for defects in complement pathways and a trial of plasma exchange is indicated.
Introduction and context
Atypical haemolytic uraemic syndrome (aHUS) belongs
to a group of thrombotic microangiopathies in which
the kidney is the primary target. It is characterised by
microangiopathic haemolytic anaemia with thrombo-
cytopenia and renal failure and is distinguished from
classical diarrhoea-associated HUS typically occurring
in childhood (caused by Shiga-toxin-producing bacteria
and with a good prognosis; >90% children recover
normal renal function with supportive therapy) and
characterized by its chronic and relapsing course. The
presentation of aHUS may overlap with classic throm-
botic thrombocytopenic purpura (TTP), a disorder
where the combination of microangiopathic haemoly-
tic anaemia and thrombocytopenia is often associated
with neurological symptoms but usually less severe
renal dysfunction. TTP is most frequently caused by a
deficiency of the von Willebrand cleaving protease
ADAMTS13 (a disintegrin and metalloproteinase with
thrombospondin motifs-13), commonly as a result of
autoantibody production and rarely as a result of
congenital deficiency of this enzyme. The evidence-
based treatment for TTP is plasma exchange (PEX) [1].
aHUS is a rare (about two cases per million people per
year in the UK) and serious condition (both inherited
and acquired forms) prone to relapses, with both a
high mortality and substantial risk of end-stage renal
disease.
Recent advances
aHUS is triggered by dysregulation of the alternative
complement activation pathway, an important defence
mechanism for the recognition and elimination of
pathogens [2]. Several different defects have been
identified overall in about 50% of cases [3,4]. The
alternative pathway is in a state of constant auto-
activation (‘tickover’) (Figure 1) and therefore requires
continuous active control. A succession of proteolytic
steps involving complement component 3 (C3) and
complement factors B and D results in an amplification
loop that enhances complement activation. Ultimately,
C5 activation results in generation of the membrane
attack complex with resultant cell lysis. Activation is
controlled by inhibitory proteins, factor H and mem-
brane-bound cofactor protein (MCP, now known as
CD46). Factor I is a serine protease that inactivates C3b
and C4b with cofactors factor H and C4b binding
protein. Abnormalities have been described in the genes
for most components (factor H [in 30% of patients],
CD46 [in 10-15% of patients], factor I [in 10% of
patients], factor B, C3, factor H-related proteins 1-5, and
thrombomodulin) [3-6], leading to the pathology and
outlook of this disease. While most mutations result in
defective function of regulatory proteins, gain-of-function
mutations can result in overactivation of the pathway
(‘super factor B’) [7,8]. Some young patients (about 10%)
have autoantibodies against factor H, particularly in a
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components (e.g., the CFHR1 [complement factor H-
related 1] gene [9]). Some patients with aHUS have
ADAMTS13deficiency.Thesefindingshavegeneratednew
guidance for diagnosis (to recognise these different
mechanisms) and management (particularly to standar-
dise and audit outcome in this rare disease), and also new
possibilities for treatment using inhibitors of the alter-
native pathway.
Implications for clinical practice
The optimal primary management of aHUS remains
unclear. The differentiation of diarrhoeal HUS from
aHUS in childhood may be difficult [5]. Because aHUS is
severe with high mortality, and difficult to distinguish
from TTP, PEX should be started immediately if aHUS is
suspected (based on expert opinion rather than clinical
trials) [5,6,10,11]. A consistent approach to treatment
may result from application of guidelines, but it is
essential that outcome data are collected from these rare
cases into a registry so that in future there is clear
evidence for treatment. Prior to infusion of plasma,
blood samples should be taken for assessment of
complement components (C3, factors H and I, anti-
factor H antibodies, and CD46) and for gene mutation
analysis (factor H, factor I, CD46, factor B, and C3) –
suitable laboratories are listed in the guidelines [5,6].
The results do not influence immediate management,
but enable some prediction to be made about the
indications and likely success of renal transplantation
(e.g., poor outcome predicted in those with mutations in
the genes encoding complement factors H or I [CFH or
CFI]). PEX daily for 5 days then tailing off over 4 more
weeks is recommended [6] but can be tailored to
individual requirements [5,6]. Patients with isolated
CD46 dysfunction (membrane bound) are unlikely to
respond to PEX (but have a better long-term outcome)
[5], in contrast to those with autoantibodies to factor H
who respond well to PEX and immunosuppression [2].
Patients with autoantibody-induced HUS who require
renal transplantation need immunosuppressive therapy
prior to and during transplantation.
New therapies are on the horizon. A monoclonal
antibody targeted against C5, eculizumab, has been
beneficial in some cases of aHUS [12,13]. A clinical trial
is underway with a target recruitment of 15 patients and
is expected to complete later this year [14]. This is an
exciting development that may offer a more beneficial
therapy in this serious disease. Other therapeutic
strategies under investigation include factor H concen-
trate, and synthetic complement regulators.
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Figure 1. Complement activation pathways
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All complement pathways converge in the production of complement
component 5 (C5) and the membrane attack complex. Inhibitors are shown
in red and include factor H (FH), factor I (FI), and CD46, which inhibit the
alternative pathway. mAb, monoclonal antibody.
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